Clinical Trials
9 trialsNCT05438043 2026-06-05
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06152575 2026-06-05
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT06158841 2026-06-05
CERVINO
AbbVie
Phase 3 Recruiting
NCT06208150 2026-06-05
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06615479 2026-06-04
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT05519085 2026-06-03
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT07623798 2026-06-03
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Not yet recruiting
NCT07555938 2026-05-27
CEVOLUTION
Hoffmann-La Roche
Phase 3 Recruiting
NCT07138209 2026-05-22
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting